1.72
Schlusskurs vom Vortag:
$1.73
Offen:
$1.75
24-Stunden-Volumen:
808.29K
Relative Volume:
0.86
Marktkapitalisierung:
$231.27M
Einnahmen:
$108.81M
Nettoeinkommen (Verlust:
$-186.70M
KGV:
-2.0428
EPS:
-0.842
Netto-Cashflow:
$-16.83M
1W Leistung:
-0.58%
1M Leistung:
+5.52%
6M Leistung:
+19.44%
1J Leistung:
+4.88%
Organigram Global Inc Stock (OGI) Company Profile
Vergleichen Sie OGI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
OGI
Organigram Global Inc
|
1.72 | 232.62M | 108.81M | -186.70M | -16.83M | -0.842 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Organigram Global Inc Stock (OGI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-17 | Fortgesetzt | Canaccord Genuity | Speculative Buy |
| 2024-04-15 | Hochstufung | Alliance Global Partners | Neutral → Buy |
| 2023-01-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-12 | Hochstufung | Canaccord Genuity | Hold → Speculative Buy |
| 2021-05-11 | Hochstufung | CIBC | Sector Underperform → Neutral |
| 2021-04-14 | Herabstufung | CIBC | Neutral → Sector Underperform |
| 2021-04-08 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2021-03-10 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2021-01-13 | Herabstufung | Alliance Global Partners | Buy → Neutral |
| 2021-01-13 | Herabstufung | Canaccord Genuity | Speculative Buy → Hold |
| 2020-07-07 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-01-15 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-01-13 | Eingeleitet | BofA/Merrill | Underperform |
| 2020-01-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-11-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-10-11 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Organigram Global Inc Aktie (OGI) Neueste Nachrichten
Cannabis Stocks To Follow TodayJanuary 10th - MarketBeat
Organigram taps James Yamanaka as CEO - MSN
Is Organigram Global Inc. stock a smart buy before Fed meetingMarket Performance Report & Consistent Growth Equity Picks - ulpravda.ru
How Organigram Global Inc. stock benefits from tech adoption2025 Short Interest & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
How Organigram Global Inc. stock responds to policy changesTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Best Cannabis Stocks To Follow TodayJanuary 8th - MarketBeat
Promising Cannabis Stocks To Add to Your WatchlistJanuary 3rd - MarketBeat
Why Organigram Global Inc. (0OG) stock could break out in 2025Retail Investor Activity & Big Profit Low Trading - ulpravda.ru
Will Organigram Global Inc. (0OG) stock extend growth story2026 world cup usa national team round of 32 goalkeepers pressing system winner prediction tactical review - ulpravda.ru
Cannabis Stocks To ResearchJanuary 2nd - MarketBeat
SA Quant ranks cannabis stocks as Trump signs rescheduling order - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Three pot stocks analysts love right now - Cantech Letter
Organigram Holdings Is Suddenly Everywhere — But Is OGI Stock Actually Worth the Hype? - AD HOC NEWS
Organigram Global Inc. (OGI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Best Cannabis Stocks To Watch TodayDecember 29th - MarketBeat
Organigram deepens Phylos partnership to secure long-term cannabis genetics edge - MSN
Organigram expands Phylos partnership to secure cannabis genetics By Investing.com - Investing.com Nigeria
Best Cannabis Stocks To ResearchDecember 28th - MarketBeat
Organigram extends innovation investment with Phylos - StratCann
Toronto Stocks Edge Lower; Organigram Increases Investment in Phylos Bioscience - marketscreener.com
Organigram Deepens Phylos Partnership to Secure Long-Term Cannabis Genetics Edge - TipRanks
Organigram (OGI) Expands Innovation Investment with Phylos Biosc - GuruFocus
Organigram expands Phylos partnership to secure cannabis genetics - Investing.com
Organigram Invests Additional $3 Million Into Phylos Bioscence (NASDAQ:OGI) - Seeking Alpha
Organigram Extends Innovation Investment with Phylos - Business Wire
Organigram Global Q4 Earnings Call Highlights - MarketBeat
Organigram Stock Jumps Amid Strategic Moves and Market Shifts - StocksToTrade
Organigram Global Inc. (NASDAQ:OGI) Q4 2025 Earnings Call Transcript - Insider Monkey
Organigram Global (OGI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Organigram Global (TSX:OGI) Market Participants React To TSX Smallcap Index Trends - Kalkine Media
Organigram: Premium Pivot Signals Further Margin Expansion (NASDAQ:OGI) - Seeking Alpha
Organigram Global (OGI) price target increased by 15.25% to 2.53 - MSN
How Investors May Respond To Organigram Global (TSX:OGI) 2025 Loss And 2026 Revenue Guidance Above CAD 300 Million - Yahoo Finance
Is Organigram Global Inc. stock attractive for hedge fundsTrade Exit Report & Fast Moving Stock Watchlists - Улправда
Is Organigram Global Inc. (0OG) stock undervalued after correctionWeekly Trading Summary & Weekly Market Pulse Alerts - Улправда
Why retail investors pile into Organigram Global Inc. stockJuly 2025 Reactions & Real-Time Chart Breakout Alerts - Улправда
3 Best Cannabis Stocks: Will They Fly High Again Post Trump Schedule III? - Seeking Alpha
Will Organigram Global Inc. stock benefit from AI adoption2025 Geopolitical Influence & Reliable Price Action Trade Plans - DonanımHaber
Organigram Global Inc. (TSE:OGI) Soars 33% But It's A Story Of Risk Vs Reward - simplywall.st
Finanzdaten der Organigram Global Inc-Aktie (OGI)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):